Navigation Links
58% of Physicians Support FDA Move to Pull Breast Cancer Indication from Avastin
Date:2/4/2011

CAMBRIDGE, Mass., Feb. 4, 2011 /PRNewswire/ -- Sermo (http://www.sermo.com), the world's largest online community for physicians, announced the publication of a free Sermo Report about how physicians are reacting to the FDA decision to rescind the indication for Avastin (bevacizumab) in the treatment of breast cancer.  The new report titled "Should Avastin (bevacizumab) Keep its Breast Cancer Indication?" reveals how physicians are using Avastin and which therapeutic agents they will switch to for clinical presentations.

58% of physician respondents support the FDA's move to pull the breast cancer indication from Avastin. However, 50% of respondents also believe that Avastin has increased the quality of life for breast cancer patients.

Physicians provided commentary on both sides of the debate. Some believe that the progression free survival benefit previously shown for Avastin is meaningful.  According to one oncologist on Sermo, "...if folks can get 'caught up' on the survival endpoint by being able to take Avastin at the time of progression, how can one possibly prove a survival advantage overall." Another oncologist commented, "This is a shame, but we are going to do what the payers let us do."

Therapeutic agents listed by physicians that will be used instead of Avastin in the treatment of breast cancer include, but are not limited to Resveratrol, Abraxane (paclitaxel), Taxotere (docetaxel), Gemzar (gemcitabine), Xeloda (capecitabine), Abraxane (paclitaxel), Taxol (paclitaxel), Navelbine (Vinorelbine) and Ixempra (ixabepilone).

Many of the respondents also participated in an online discussion regarding the original Avastin study. The full report includes:

  • Overview of FDA decision
  • Report methodology
  • Key findings
  • Discussion highlights
  • Changes in physician perception from 2009-2010
  • Therapeutic agents physicians will use in place of Avastin

To download full results of this free report, visit sermo.com/client.

About Sermo Reports

Sermo Reports solicit perceptions and opinions from physicians about new drugs, devices, treatments, trends, and other topics of interest. Data for Sermo Reports is gathered through Sermo Posts, which allow physicians to participate in a poll and comment on the topic.  All physicians on Sermo are verified and credentialed.

About Sermo

Sermo is the largest online physician community, where over 117,000 practicing physicians discuss a wide range of issues from clinical cases to advice about drugs and practice management. By leveraging Sermo's social media platform, clients can tap into unsolicited, peer-to-peer dialog and engage MDs to gain market intelligence and increase brand awareness. For more information, visit www.sermo.com/client.


'/>"/>
SOURCE Sermo
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aprima Electronic Health Record a Top Choice for Colorado Physicians
2. Healthy Advice® Networks Physicians Discuss Patient Adherence Challenges at National Conference
3. Millennium Laboratories to Provide UnitedHealthcares Nationwide Network of Physicians Drug Monitoring and Pain Management Services
4. Consolidated Portland, Maine Healthcare Market Will Hamper Pharmaceutical Reps Access to Physicians
5. Sermo Study Shows 63% of Physicians Would Utilize New Gout Treatments
6. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
7. Activity Against Key Drug-Resistant Pathogens is the Most Important Attribute Influencing Surveyed Physicians Antibiotic Selection for Nosocomial Pneumonia in the U.S.
8. MedSolutions Offers Free CME Credit Imaging Safety Webinar for Physicians
9. Emergency Physicians Urge Americans to Take The American Medicine Chest Challenge November 13th
10. Physicians Pharmaceutical Corporation Offers Innovative On-Site Drug Dispensaries
11. Professional Liability Costs for Hospitals and Physicians Continue to Rise, Outpacing Inflation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... -- Enterin Inc., a privately-held CNS pharmaceutical company based in ... treat Parkinson,s disease (PD), has enrolled the first patient in ... controlled, multicenter study involving patients with PD and taking place ... a 9-to-12-month period. The first stage is open label and ... sites include Denver , Boca ...
(Date:5/10/2017)... 10, 2017  The Corporate Whistleblower Center says, ... sleep therapy clinics to call us anytime at ... is involved in a substantial scheme to overbill ... from an employee of a medical equipment company ... to provide medical practice groups with extra generous incentives ...
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals ... ), a clinical-stage pharmaceutical company focused on the ... that the Canadian Intellectual Property Office has granted ... Oral Administration of Exenatide". The patent covers Oramed,s ... GLP-1 is an incretin hormone that ...
Breaking Medicine Technology:
(Date:5/28/2017)... ... May 28, 2017 , ... Starting in May, patients at ... Heart Rate Variability (HRV) diagnostic test. , Nerve-Express, originally designed for the Navy in ... the state of a patient’s autonomic nervous system (ANS). The ANS controls all ...
(Date:5/28/2017)... ... May 28, 2017 , ... Florida ... to announce that Sheldon K. Cho, MD, has joined its Winter Haven practice. ... that concentrates on minimally invasive techniques to treat and manage many types of ...
(Date:5/27/2017)... ... , ... Hate visiting the dentist? You should go twice per year for checkups, but if ... at home. Here are some dental tips to help out: , 1. Brushing Teeth - ... work desk or a locker at school for a quick brushing after lunch. Use a ...
(Date:5/27/2017)... ... May 27, 2017 , ... Most us are familiar with the sound of ... from the Osteoarthritis Initiative shows that certain people who experience consistent joint popping, ... may give doctors the opportunity to treat patients before the problem becomes pronounced, potentially ...
(Date:5/26/2017)... Massachsetts (PRWEB) , ... May 26, 2017 , ... ... will gather at Boston CEO 2017 on May 30th and 31st at The ... networking forum for leading executives in the life sciences, offering exclusive access to ...
Breaking Medicine News(10 mins):